Batimastat matrix metalloproteinase inhibitor data

BBIOY (Oxford, U.K.) announced early results of a Phase I/II trial showing that patients reaccumulated pleural fluid more slowly after being given the agent, and that the drug was well tolerated.

As reported at the meeting of the British Association for Cancer Research in Nottingham, five doses were tested, with three patients included at each dose level. Patients treated with 60 to 135 mg/m 2 required less frequent drainage of the fluid in their chests (p<0.001). ...